Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts.
about
Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort studyCan non-physician health-care workers assess and manage cardiovascular risk in primary care?VTE Risk assessment - a prognostic Model: BATER Cohort Study of young womenThe role of guidelines and the patient's life-style in GPs' management of hypercholesterolaemiaReassessing the Usefulness of Coronary Artery Calcium Score among Varying Racial and Ethnic Groups by Geographic Locations: Relevance of the Korea Initiatives on Coronary Artery Calcification RegistryCardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events ofRisk factors for ischaemic heart disease in a Cretan rural population: a twelve year follow-up studyImplementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: lessons learned from a health care services studyAn evidence-based shared decision making programme on the prevention of myocardial infarction in type 2 diabetes: protocol of a randomised-controlled trialA coronary heart disease prediction model: the Korean Heart Study.Outcome of coronary plaque burden: a 10-year follow-up of aggressive medical management.The research on endothelial function in women and men at risk for cardiovascular disease (REWARD) study: methodology.Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands.Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up studyIn-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro studyThe accuracy of the Framingham risk-score in different socioeconomic groups: a prospective studyEstimating the risk of developing type 2 diabetes: a comparison of several risk scores: the Cohorte Lausannoise studyEffectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model.Cardiovascular risk factor distribution and subjective risk estimation in urban women--the BEFRI study: a randomized cross-sectional study.Comparison of Framingham, PROCAM, SCORE, and Diamond Forrester to predict coronary atherosclerosis and cardiovascular eventsOriginal and REGICOR Framingham functions in a nondiabetic population of a Spanish health care center: a validation studyAn informed shared decision making programme on the prevention of myocardial infarction for patients with type 2 diabetes in primary care: protocol of a cluster randomised, controlled trialCardiovascular risk perception in women: true unawareness or risk miscalculation?By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease.Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review.Agreement Between Cardiovascular Disease Risk Scores in Resource-Limited Settings: Evidence from 5 Peruvian Sites.High Risk versus Proportional Benefit: Modelling Equitable Strategies in Cardiovascular PreventionAccuracy of self-perception of cardiovascular risk in the communityMethodological issues in cardiovascular epidemiology: the risk of determining absolute risk through statistical models.Comparison of the Framingham Risk Score, UKPDS Risk Engine, and SCORE for Predicting Carotid Atherosclerosis and Peripheral Arterial Disease in Korean Type 2 Diabetic Patients.Predicting 10-Year Risk of Fatal Cardiovascular Disease in Germany: An Update Based on the SCORE-Deutschland Risk Charts.Recalibration of the ACC/AHA Risk Score in Two Population-Based German Cohorts.Treatment of dyslipidaemia in HIV-infected persons.Performance of the Framingham and SCORE cardiovascular risk prediction functions in a non-diabetic population of a Spanish health care centre: a validation studyComparison of subclinical coronary atherosclerosis and risk factors in unselected populations in Germany and US-America.Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to dateThe importance of total cardiovascular risk assessment in clinical practice.Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population.Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians.Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study.
P2860
Q24630111-B5D7CA62-DB1E-4BC0-8D5B-C204B454AA31Q24657952-C8889925-EE7C-4A67-831D-B3537A435292Q24795738-F5634C98-25E4-4588-923C-08CBF28345F3Q24806073-DBE533F8-7150-4DC6-81AA-93ADDD1B08B5Q26772283-3F795B9C-FE39-4452-A7AC-5AECCD0EEE04Q30987054-9F75470E-FD00-4348-9E51-882DE2E27413Q33311009-8EB66D13-E53E-412A-91E6-381C92E8D55AQ33352311-C8B9C68B-72BA-49ED-B204-4F83B4C6247FQ33592897-CE02BDE8-0C96-48ED-848A-EC543DE559FEQ33691318-C5A54366-EDEF-4049-BDAC-FD4605B278B0Q33772661-5495BDBA-7693-4C49-8D66-7CE8CDF1C865Q33989516-9BA955BC-66BD-4F02-9860-2575E0ADF48AQ34207158-8F767C2F-FB94-479E-A30A-3D9BBDB37E93Q34273907-577B6C76-C486-46B1-A1AB-5FB64425BE0DQ34557332-DADEF207-033A-4E82-8833-494314357E46Q35040566-0E7C0536-01F1-4CB8-A3AD-CC92343A5265Q35123393-8D8F9D8B-85E9-4796-B91B-A07BE547F9FAQ35203211-DC68ACCC-C6A8-414A-A245-4E46C3A4C006Q35215536-F4673370-1356-4AC1-B1B5-97185CCB79C1Q35218207-2128B78A-EC24-4378-8C82-49444C5EDF60Q35259627-DBEBC6E9-02AD-4E8E-8F08-26E8D9CD727CQ35341424-220BFDBF-7672-46EE-9BF0-924D4E753AC3Q35595708-6091A446-EAE4-4A94-BE58-E4824DD9BAA7Q35771476-94E68907-D278-4A7D-8A66-36D7DB01D1F7Q35772791-403D334C-A8A0-4EE8-BB9B-689849E4A325Q35776957-CE90F3FC-3EA5-42BB-BB35-519160A1C71AQ35830679-5BD98386-CDAC-4A12-8EAF-4F45E93AEB3BQ35865207-CA8D3576-AAED-47A6-A37A-759868FFD591Q36012946-CA629140-3D28-47C0-8484-55A046A4330FQ36058307-9301B6D0-8DB0-41EC-83CE-5D5FE8779D48Q36128563-AC1C2DEF-3420-4967-88EB-1E8C3AA35721Q36161516-C527F424-E3E2-44AF-9B58-2928BB31F76FQ36222023-1066FB76-6A51-40D4-A068-2FAC4F040495Q36241155-4E77F49F-1863-4E7E-995A-BF0D46259CEAQ36540355-AA24749A-DA13-4321-9D7B-0074AEBBB48AQ36643600-8B196B11-9C88-46C1-B3ED-07A812ECCD52Q36664880-C14491E7-2C52-434A-A653-DD29467A473BQ36766928-580757F4-A38B-4807-A216-6BC97414045DQ36766993-B82183F9-A8E9-4CC8-9021-CCA6729A59C6Q36768750-487B347A-80F0-4ACE-B1C1-D0A9BC3B33F1
P2860
Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Framingham risk function overe ...... gsburg and the PROCAM cohorts.
@en
Framingham risk function overe ...... gsburg and the PROCAM cohorts.
@nl
type
label
Framingham risk function overe ...... gsburg and the PROCAM cohorts.
@en
Framingham risk function overe ...... gsburg and the PROCAM cohorts.
@nl
prefLabel
Framingham risk function overe ...... gsburg and the PROCAM cohorts.
@en
Framingham risk function overe ...... gsburg and the PROCAM cohorts.
@nl
P2093
P1476
Framingham risk function overe ...... gsburg and the PROCAM cohorts.
@en
P2093
Gerd Assmann
Hannelore Löwel
Hans-Werner Hense
Helmut Schulte
Ulrich Keil
P304
P356
10.1016/S0195-668X(03)00081-2
P577
2003-05-01T00:00:00Z